Natura &Co Holding completes corporate simplification in 2025

Natura &Co Holding S.A. held its Q4 2025 earnings call on March 17, 2026. CEO João Paulo Brotto Ferreira described 2025 as a watershed year, marked by the completion of a corporate simplification cycle started in 2022.

Natura &Co Holding S.A. (NTCOY), which now trades under the ticker NATU3 following a reverse merger, conducted its Q4 2025 earnings call on March 17, 2026, at 8:00 AM EDT. The call featured João Paulo Brotto Ferreira, CEO of Latin America and member of the executive board, and Silvia Lopes Vilas Magalhaes, CFO and IR officer. Analysts from firms including XP Investimentos, JPMorgan Chase, Itaú Corretora, Morgan Stanley, Citigroup, and Goldman Sachs participated via conference call. A slide deck was posted to the company's IR website beforehand. In his opening remarks, Ferreira stated: '2025 was a watershed year for the company as we finally wrapped up the corporate simplification cycle we kicked off back in 2022 and led by Fabio Barbosa.' He highlighted key achievements, including the divestiture of Avon International, Avon CARD, and Avon Russia over the past year. The company also streamlined its holding structure through the reverse merger, restoring trading under NATU3. Operationally, Natura &Co completed Wave 2 integration in Mexico and Argentina. Ferreira concluded: 'As a consequence, the company is back to basics, with a laser focus on our core Latin American operations.' The call emphasized a return to core operations after these restructuring efforts.

Связанные статьи

Nuvation Bio Inc. conducted its first quarter 2026 earnings call on May 4, 2026. The company reviewed financial results for the period ending March 31, 2026, and provided a business update. Executives including CEO David Hung participated in the discussion.

Сообщено ИИ

Wacoal Holdings Corp released a slide deck for its 2026 Q4 earnings call on May 24. The materials were issued alongside the quarterly results discussion.

Aytu BioPharma conducted its earnings call for the fiscal 2026 third quarter on May 13, 2026. Executives discussed operational and financial results for the period ended March 31, 2026.

Сообщено ИИ

ARS Pharmaceuticals held its first quarter 2026 earnings conference call on May 15, highlighting early momentum in the new year. Company executives emphasized growth drivers including expanded access for its neffy product. The call featured forward-looking statements about the firm's commercial progress.

Этот сайт использует куки

Мы используем куки для анализа, чтобы улучшить наш сайт. Прочитайте нашу политику конфиденциальности для дополнительной информации.
Отклонить